Literature DB >> 10611737

Myristic acid analogs are inhibitors of Junin virus replication.

S M Cordo1, N A Candurra, E B Damonte.   

Abstract

The effects of two myristic acid analogs on Junin virus (JV) replication were investigated. The compounds chosen for the study were DL-2-hydroxymyristic acid (2OHM), an inhibitor of N-myristoyltransferase (NMT), which binds the enzyme and blocks protein myristoylation, and 13-oxamyristic acid (13OM), a competitive inhibitor of NMT which incorporates into the protein instead of myristic acid. Both types of analogs achieved dose-dependent inhibition of viral multiplication at concentrations not affecting cell viability. The 50% inhibitory concentration values determined by a virus-yield inhibition assay for different strains of JV, including a human pathogenic strain, and for the related arenavirus, Tacaribe, were in the range 1.6 to 20.1 microM, with 13OM as the most active compound. From time of addition and removal experiments, it can be concluded that both analogs inhibit a late stage in the JV replicative cycle, and their effect was partially reversible. The cytoplasmic and surface expression of JV glycoproteins was not affected in the presence of the compounds, as revealed by immunofluorescence staining, suggesting that JV glycoprotein myristoylation would not be essential for the intracellular transport of the envelope proteins, but it may have an important role in their interaction with the plasma membrane during virus budding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10611737     DOI: 10.1016/s1286-4579(99)80060-4

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  18 in total

1.  Myristoylation of the RING finger Z protein is essential for arenavirus budding.

Authors:  Mar Perez; Dori L Greenwald; Juan Carlos de la Torre
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 2.  Novel approaches in anti-arenaviral drug development.

Authors:  Andrew M Lee; Antonella Pasquato; Stefan Kunz
Journal:  Virology       Date:  2010-12-22       Impact factor: 3.616

3.  Mutations in the amino terminus of foamy virus Gag disrupt morphology and infectivity but do not target assembly.

Authors:  Rachel B Life; Eun-Gyung Lee; Scott W Eastman; Maxine L Linial
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

Review 4.  Progress in the experimental therapy of severe arenaviral infections.

Authors:  Brian B Gowen; Mike Bray
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

5.  Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds.

Authors:  Cybele C García; Mahmoud Djavani; Ivan Topisirovic; Katherine L B Borden; María S Salvato; Elsa B Damonte
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

6.  Membrane saturated fatty acids and disease progression in multiple sclerosis patients.

Authors:  G M Hon; M S Hassan; S J van Rensburg; S Abel; R T Erasmus; T Matsha
Journal:  Metab Brain Dis       Date:  2009-11-05       Impact factor: 3.584

7.  The signal peptide of the Junín arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex.

Authors:  Joanne York; Victor Romanowski; Min Lu; Jack H Nunberg
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 8.  Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever.

Authors:  Lisa McLay; Aftab Ansari; Yuying Liang; Hinh Ly
Journal:  Antiviral Res       Date:  2012-12-20       Impact factor: 5.970

Review 9.  Reverse genetics approaches to combat pathogenic arenaviruses.

Authors:  Juan C de la Torre
Journal:  Antiviral Res       Date:  2008-09-07       Impact factor: 5.970

10.  Identification of Inhibitory Compounds Against Singapore Grouper Iridovirus Infection by Cell Viability-Based Screening Assay and Droplet Digital PCR.

Authors:  Kuntong Jia; Yongming Yuan; Wei Liu; Lan Liu; Qiwei Qin; Meisheng Yi
Journal:  Mar Biotechnol (NY)       Date:  2017-12-05       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.